[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Spyre Therapeutics Inc 221 CRESCENT STREET BUILDING 23 SUITE 105 WALTHAM MA 02453 USA

www.spyre.com Employees: 102 P: 617-651-5940

Sector:

Medical

Description:

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based in WALTHAM, Mass.

Key Statistics

Overview:

Market Capitalization, $K 5,664,569
Enterprise Value, $K 5,734,669
Shares Outstanding, K 78,784
Float, K 66,423
% Float 84.31%
Short Interest, K 11,673
Short Float 14.82%
Days to Cover 7.35
Short Volume Ratio 0.54
% of Insider Shareholders 15.69%
% of Institutional Shareholders 80.39%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -155,200 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -62,530 K
EBIT, $ -209,570 K
EBITDA, $ -220,970 K

Growth:

1-Year Return 380.98%
3-Year Return 1,697.50%
5-Year Return -60.28%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 94.79%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.70 on 02/19/26
Next Earnings Date 05/14/26 [--]
Earnings Per Share ttm -2.08
EPS Growth vs. Prev Qtr -366.67%
EPS Growth vs. Prev Year 13.58%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 09/08/23

SYRE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -41.79%
Return-on-Assets % -25.96%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 9.66
Book Value/Share 9.22
Interest Coverage -3.09
60-Month Beta 2.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.